Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


12.11.2018

1 AJR Am J Roentgenol
2 Arch Esp Urol
1 BMC Anesthesiol
2 BMC Urol
1 BMJ Case Rep
1 Cancer Biol Ther
1 Cancer Sci
1 Carcinogenesis
1 Cell Physiol Biochem
2 Clin Cancer Res
2 Curr Urol Rep
3 Eur Urol
1 Exp Cell Res
1 Int J Biol Macromol
1 Int J Nanomedicine
1 J Cell Mol Med
2 J Urol
2 Med Sci Monit
1 Mol Cancer Res
1 Oncoimmunology
1 Oncol Lett
1 Pathol Res Pract
1 ScientificWorldJournal
1 Surgery
10 Urol Oncol
1 Vet Pathol
3 World J Urol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. WOO S, Suh CH, Kim SY, Cho JY, et al
    The Diagnostic Performance of MRI for Detection of Lymph Node Metastasis in Bladder and Prostate Cancer: An Updated Systematic Review and Diagnostic Meta-Analysis.
    AJR Am J Roentgenol. 2018 Jan 30:W1-W15. doi: 10.2214/AJR.17.18481.
    PubMed     Text format     Abstract available


    Arch Esp Urol

  2. CALLEJA P, Dominguez M, Ramos E, Carrion CJ, et al
    [Hyponatremia as a presenting sign of metastatic disease in muscle invasive bladder cancer.]
    Arch Esp Urol. 2018;71:799-804.
    PubMed     Text format     Abstract available

  3. GUL M, Goktas S, Kars MD, Kaynar M, et al
    Drug resistance restricts the efficacy of short term low dose Mitomycin-C treatment in UMUC-3 bladder cancer cells.
    Arch Esp Urol. 2018;71:783-793.
    PubMed     Text format     Abstract available


    BMC Anesthesiol

  4. CHIPOLLINI J, Alford B, Boulware DC, Forget P, et al
    Epidural anesthesia and cancer outcomes in bladder cancer patients: is it the technique or the medication? A matched-cohort analysis from a tertiary referral center.
    BMC Anesthesiol. 2018;18:157.
    PubMed     Text format     Abstract available


    BMC Urol

  5. MANSOUR AM, Abdelrahim M, Laymon M, Elsherbeeny M, et al
    Epidermal growth factor expression as a predictor of chemotherapeutic resistance in muscle-invasive bladder cancer.
    BMC Urol. 2018;18:100.
    PubMed     Text format     Abstract available

  6. KAWAHARA T, Ishiguro Y, Ohtake S, Kato I, et al
    PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer.
    BMC Urol. 2018;18:97.
    PubMed     Text format     Abstract available


    BMJ Case Rep

  7. KASE AM, Menke D, Tan W
    Breast cancer metastasis to the bladder: a literature review.
    BMJ Case Rep. 2018;2018.
    PubMed     Text format     Abstract available


    Cancer Biol Ther

  8. TENG J, Ai X, Jia Z, Wang K, et al
    Long non-coding RNA ARAP1-AS1 promotes the progression of bladder cancer by regulating miR-4735-3p/NOTCH2 axis.
    Cancer Biol Ther. 2018 Nov 7:1-10. doi: 10.1080/15384047.2018.1538613.
    PubMed     Text format     Abstract available


    Cancer Sci

  9. TIAN DW, Wu ZL, Jiang LM, Gao J, et al
    NEDD8 promotes the tumor progression and predicts the poor prognosis of patients with bladder cancer.
    Cancer Sci. 2018 Nov 8. doi: 10.1111/cas.13865.
    PubMed     Text format     Abstract available


    Carcinogenesis

  10. KOIVISTO M, Tervahartiala M, Kenessey I, Jalkanen S, et al
    Cell-type specific CD73 expression is an independent prognostic factor in bladder cancer.
    Carcinogenesis. 2018 Nov 3. pii: 5160033. doi: 10.1093.
    PubMed     Text format     Abstract available


    Cell Physiol Biochem

  11. HE RQ, Huang ZG, Li TY, Wei YP, et al
    RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update.
    Cell Physiol Biochem. 2018;50:1474-1495.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  12. CHEN X, Xie R, Gu P, Huang M, et al
    Long noncoding RNA LBCS inhibits self-renewal and chemoresistance of bladder cancer stem cells through epigenetic silencing of SOX2.
    Clin Cancer Res. 2018 Nov 5. pii: 1078-0432.CCR-18-1656.
    PubMed     Text format     Abstract available

  13. WANG KJ, Wang C, Dai LH, Yang J, et al
    Targeting an Autocrine Regulatory Loop in Cancer Stem-Like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer.
    Clin Cancer Res. 2018 Nov 5. pii: 1078-0432.CCR-18-0586.
    PubMed     Text format     Abstract available


    Curr Urol Rep

  14. BHANVADIA SK
    Bladder Cancer Survivorship.
    Curr Urol Rep. 2018;19:111.
    PubMed     Text format     Abstract available

  15. CHANDRASEKAR T, Erlich A, Zlotta AR
    Molecular Characterization of Bladder Cancer.
    Curr Urol Rep. 2018;19:107.
    PubMed     Text format     Abstract available


    Eur Urol

  16. BABJUK M
    Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-grade Non-muscle-invasive Bladder Cancer on Tumor Recurrence.
    Eur Urol. 2018 Oct 31. pii: S0302-2838(18)30827.
    PubMed     Text format    

  17. GOODSPEED A, Jean A, Costello JC
    A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
    Eur Urol. 2018 Nov 7. pii: S0302-2838(18)30835.
    PubMed     Text format     Abstract available

  18. COLOMBO R, Rocchini L, Suardi N, Benigni F, et al
    Corrigendum re "Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non-muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study" [Eur Urol 2012;62:797-802].
    Eur Urol. 2018 Nov 5. pii: S0302-2838(18)30662.
    PubMed     Text format    


    Exp Cell Res

  19. WANG F, Wu D, Chen J, Chen S, et al
    Long non-coding RNA HOXA-AS2 promotes the migration, invasion and stemness of bladder cancer via regulating miR-125b/Smad2 axis.
    Exp Cell Res. 2018 Nov 6. pii: S0014-4827(18)31122.
    PubMed     Text format     Abstract available


    Int J Biol Macromol

  20. LIU A, Zeng S, Lu X, Xiong Q, et al
    Overexpression of G2 and S phase-expressed-1 contributes to cell proliferation, migration, and invasion via regulating p53/FoxM1/CCNB1 pathway and predicts poor prognosis in bladder cancer.
    Int J Biol Macromol. 2018 Nov 8. pii: S0141-8130(18)33945.
    PubMed     Text format     Abstract available


    Int J Nanomedicine

  21. ZHAO X, Qi T, Kong C, Hao M, et al
    Photothermal exposure of polydopamine-coated branched Au-Ag nanoparticles induces cell cycle arrest, apoptosis, and autophagy in human bladder cancer cells.
    Int J Nanomedicine. 2018;13:6413-6428.
    PubMed     Text format     Abstract available


    J Cell Mol Med

  22. RUI X, Wang L, Pan H, Gu T, et al
    LncRNA GAS6-AS2 promotes bladder cancer proliferation and metastasis via GAS6-AS2/miR-298/CDK9 axis.
    J Cell Mol Med. 2018 Nov 5. doi: 10.1111/jcmm.13986.
    PubMed     Text format     Abstract available


    J Urol

  23. CHANG SS
    Re: Contemporary Use Trends and Survival Outcomes in Patients Undergoing Radical Cystectomy or Bladder-Preservation Therapy for Muscle-Invasive Bladder Cancer.
    J Urol. 2018;200:497.
    PubMed     Text format    

  24. CHANG SS
    Re: Association between Number of Endoscopic Resections and Utilization of bacillus Calmette-Guerin Therapy for Patients with High-Grade, Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2018;200:496-497.
    PubMed     Text format    


    Med Sci Monit

  25. WU L, He S, He Y, Wang X, et al
    IC-2 Suppresses Proliferation and Induces Apoptosis of Bladder Cancer Cells via the Wnt/beta-Catenin Pathway.
    Med Sci Monit. 2018;24:8074-8080.
    PubMed     Text format     Abstract available

  26. GONG X, Liu J, Zhang X, Dong F, et al
    Rab11 Functions as an Oncoprotein via Nuclear Factor kappa B (NF-kappaB) Signaling Pathway in Human Bladder Carcinoma.
    Med Sci Monit. 2018;24:5093-5101.
    PubMed     Text format     Abstract available


    Mol Cancer Res

  27. GARINET S, Pignot G, Vacher S, Le Goux C, et al
    High prevalence of a hotspot of non-coding somatic mutations in intron 6 of GPR126 in bladder cancer.
    Mol Cancer Res. 2018 Nov 6. pii: 1541-7786.MCR-18-0363.
    PubMed     Text format     Abstract available


    Oncoimmunology

  28. LIU Z, Zhu Y, Xu L, Zhang J, et al
    Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer.
    Oncoimmunology. 2018;7:e1474317.
    PubMed     Text format     Abstract available


    Oncol Lett

  29. ZHANG H, Jiang M, Liu Q, Han Z, et al
    miR-145-5p inhibits the proliferation and migration of bladder cancer cells by targeting TAGLN2.
    Oncol Lett. 2018;16:6355-6360.
    PubMed     Text format     Abstract available


    Pathol Res Pract

  30. LIU K, Zhao K, Wang L, Sun E, et al
    The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer.
    Pathol Res Pract. 2018;214:1074-1080.
    PubMed     Text format     Abstract available


    ScientificWorldJournal

  31. BUKHARI N, Al-Shamsi HO, Azam F
    Update on the Treatment of Metastatic Urothelial Carcinoma.
    ScientificWorldJournal. 2018;2018:5682078.
    PubMed     Text format     Abstract available


    Surgery

  32. SHAHA AR, Tuttle RM
    Reply: Active Surveillance in Micropapillary Carcinoma.
    Surgery. 2018;163:1325-1329.
    PubMed     Text format    


    Urol Oncol

  33. SCHLUTERMANN D, Skowron MA, Berleth N, Bohler P, et al
    Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.
    Urol Oncol. 2018;36:160.
    PubMed     Text format     Abstract available

  34. LEE HL, Chiou HL, Wang SS, Hung SC, et al
    WISP1 genetic variants as predictors of tumor development with urothelial cell carcinoma.
    Urol Oncol. 2018;36:160.
    PubMed     Text format     Abstract available

  35. VADASZ Z, Rubinstein J, Bejar J, Sheffer H, et al
    Overexpression of semaphorin 3A in patients with urothelial cancer.
    Urol Oncol. 2018;36:161.
    PubMed     Text format     Abstract available

  36. FURRER MA, Schneider MP, Burkhard FC, Wuethrich PY, et al
    Incidence and perioperative risk factors for early acute kidney injury after radical cystectomy and urinary diversion.
    Urol Oncol. 2018;36:306.
    PubMed     Text format     Abstract available

  37. HA A, Krasnow RE, Mossanen M, Nagle R, et al
    A contemporary population-based analysis of the incidence, cost, and outcomes of postoperative delirium following major urologic cancer surgeries.
    Urol Oncol. 2018;36:341.
    PubMed     Text format     Abstract available

  38. LIEM EIML, McCormack M, Chan ESY, Matsui Y, et al
    Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial.
    Urol Oncol. 2018;36:338.
    PubMed     Text format     Abstract available

  39. WINTERS BR, Vakar-Lopez F, Brown L, Montgomery B, et al
    Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy.
    Urol Oncol. 2018;36:342.
    PubMed     Text format     Abstract available

  40. SCARBERRY K, Berger NG, Scarberry KB, Agrawal S, et al
    Improved surgical outcomes following radical cystectomy at high-volume centers influence overall survival.
    Urol Oncol. 2018;36:308.
    PubMed     Text format     Abstract available

  41. VAN DE KAMP M, Meijer R, Pos F, Kerst M, et al
    Intravesical recurrence after bladder sparing treatment of small cell carcinoma of the bladder: Characteristics, treatment, and outcome.
    Urol Oncol. 2018;36:307.
    PubMed     Text format     Abstract available

  42. SMITH AB, Meyer AM, Meng K, Nielsen ME, et al
    The relationship of travel distance with cystectomy access and outcomes.
    Urol Oncol. 2018;36:308.
    PubMed     Text format     Abstract available


    Vet Pathol

  43. LIN SJ, Kao CF, Wang FI, Jeng CR, et al
    Urothelial Carcinomas of the Urinary Bladder With Plasmacytoid or Rhabdoid Features and Tendency of Epithelial-Mesenchymal Transition in 3 Dogs.
    Vet Pathol. 2018;55:673-677.
    PubMed     Text format     Abstract available


    World J Urol

  44. DUPLISEA JJ, Mokkapati S, Plote D, Schluns KS, et al
    The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside.
    World J Urol. 2018 Nov 11. pii: 10.1007/s00345-018-2553.
    PubMed     Text format     Abstract available

  45. LYON TD, Frank I, Sharma V, Shah PH, et al
    A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease.
    World J Urol. 2018 Nov 3. pii: 10.1007/s00345-018-2551.
    PubMed     Text format     Abstract available

  46. SCHARDT J, Roth B, Seiler R
    Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?
    World J Urol. 2018 Nov 3. pii: 10.1007/s00345-018-2544.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: